Upcoming event

Accuracy of fully automated, AI-generated models compared with validated clinical model to predict post-operative glomerular filtration rate after renal surgery

Burden of surgeries and surgical complications in patients with Von Hippel Lindau (VHL) disease before and after treatment with belzutifan

Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC)

Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK)

STARLITE 2: Phase 2 study of nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)

Three-dimensional model-assisted minimally invasive partial nephrectomy: A systematic review with meta-analysis of comparative studies

European Urology Oncology, December 2022

Three-dimensional model-assisted minimally invasive partial nephrectomy: A systematic review with meta-analysis of comparative studies

Oncological and peri-operative outcomes of percutaneous cryoablation of renal cell carcinoma for patients with hereditary RCC diseases – An analysis of European multi-centre prospective EuRECA registry

Is adjuvant immunotherapy worth for all patients with clear-cell renal cell carcinoma at high risk of recurrence?

Deciphering the relationship between pathogenic variants and clinical phenotype in VHL patients: results from a prospective observational study

Development of an individual postoperative prediction model for kidney cancer recurrence using machine learning (UroCCR study 120)

Quality of life outcomes after robotic-assisted versus open partial nephrectomy: Results from the randomized ROBOCOP II trial

PreviousNext